Anthem Biosciences Ltd.
ANTHEM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹247.57.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%21.7%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✓Revenue growth > 10%26%
- ✓Earnings growing127%
- ✓Net margin ≥ 10%27.9%
- ✓Current ratio > 1.55.54
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 69.32
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (21.7%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (27.9%).
- •Financially solid — Altman Z 69.32.
- •High Piotroski quality score (7/9).
Opportunities
- •Earnings growing (127% YoY).
- •Revenue growing (26% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~60% above our estimated fair value.
About Anthem Biosciences Ltd.
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of mo
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.